Perception on genetic testing in Korean medicine doctors: A mobile-based survey

다국어 초록 (Multilingual Abstract)

Background: Currently, genetic testing is widely used to understand individual characteristics. In Korea, genetic testing has been in use, but not actively in Korean Medicine (KM). To examine the perceptions of genetic testing, we performed online survey to Korean Medicine doctors (KMDs).
Methods: The survey was a mobile-based study that was developed by 6 survey specialists based on electronic database search results. The questionnaire consisted of 6 categories: general characteristics of respondents, understanding of genetic testing, demand for using genetic testing, application field and utilization level of genetic testing, limitations of genetic testing, and plans and necessary efforts to begin using genetic testing based on an 11-point Likert scale.
Results: With the response rate of 27.2% (n = 544), 46.9% of respondents answered that they understood the definition and mechanism of genetic testing. About 80% of KMDs responded that they would be willing to use genetic testing results; a notable reason for this was the need for more objective and evidence-based test results. KMDs recognized that genetic testing could not only provide personalized treatment and care, but also help communicate with patients.
Conclusions: This study observed KMDs’ perceptions of the potential clinical benefits of genetic testing. We confirmed that development of genetic testing technology, knowledge of their use, and new technology-friendly policies are essential for expanding the genetic testing technology in Korean medicine.

참고문헌 (Reference)

1 박임수, "소비자의뢰 유전자검사 구매 의도 및 목적에 영향을 미치는 요인 연구" 한국디지털정책학회 17 (17): 167-177, 2019

2 송성환, "세계 전통의학 동향과 주요 한의학 R&D 분야에 관한 연구" 한국한의학연구원 16 (16): 101-109, 2010

3 김종원, "규제 샌드박스와 질병 관련 소비자직접 의뢰 유전자검사의 확대" 대한의사협회 62 (62): 240-242, 2019

4 전명희, "국내 고위험 유전성 유방암 환자의 유전자검사 경험" 대한종양간호학회 5 (5): 146-158, 2005

5 Hauser D, "Views of primary care providers on testing patients for genetic risks for common chronic diseases" 37 : 793-800, 2018

6 Guo F, "Use of BRCA mutation test in the US, 2004–2014" 52 : 702-709, 2017

7 Wieacker P, "The prenatal diagnosis of genetic diseases" 107 : 857-862, 2010

8 Cha S, "The obesity-risk variant of FTO is inversely related with the So-Eum constitutional type : genome-wide association and replication analyses" 15 : 120-, 2015

9 Leighton J, "The general public’s understanding and perception of direct-to-consumer genetic test results" 15 : 11-21, 2012

10 Hogarth S, "The current landscape for direct-to-consumer genetic testing : legal, ethical, and policy issues" 9 : 161-182, 2008

11 Haga SB, "Survey of US public attitudes toward pharmacogenetic testing" 12 : 197-204, 2012

12 H. CS, "Relationship between the sasang constitution and ace polymorphism" 10 : 283-290, 1998

13 Agurs-Collins T, "Public awareness of direct-to-consumer genetic tests : findings from the 2013 US Health Information National Trends Survey" 30 : 799-807, 2015

14 Mirnezami R, "Preparing for precision medicine" 366 : 489-491, 2012

15 Jameson JL, "Precision medicine–personalized, problematic, and promising" 372 : 2229-2234, 2015

16 Acumen Research and Consulting, "Precision Medicine Market By Technology:(Big Data Analytics, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Others); By Application: (Oncology, Immunology, CNS, Respiratory); By End Use: (Home care, Hospitals, Clinical Laboratories, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019–2026"

17 Chase GA, "Physicians’propensity to offer genetic testing for Alzheimer’s disease : results from a survey" 4 : 297-303, 2002

18 Roses AD, "Pharmacogenetics and drug development : the path to safer and more effective drugs" 5 : 645-656, 2004

19 Childers CP, "National estimates of genetic testing in women with a history of breast or ovarian cancer" 35 : 3800-, 2017

20 Topol EJ, "Individualized medicine from prewomb to tomb" 157 : 241-253, 2014

21 Research and Markets, "Global Consumer DNA (Genetic) Testing Market -Forecasts from 2018–2023"

22 Offit K, "Genomic profiles for disease risk : predictive or premature" 299 : 1353-1355, 2008

23 Phillips KA, "Genetic test availability and spending: where are we now? Where are we going?" 37 : 710-716, 2018

24 Grant RW, "Genetic architecture of type 2 diabetes : recent progress and clinical implications" 32 : 1107-1114, 2009

25 Kim B-Y, "Genetic approach to elucidation of sasang constitutional medicine" 6 : 51-57, 2009

26 Khoury MJ, "From genes to public health: The applications of genetic technology in disease prevention. Genetics Working Group" 86 : 1717-1722, 1996

27 Tandy-Connor S, "False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care" 20 : 1515-, 2018

28 김형규, "Energy metabolism and whole-exome sequencing-based analysis of Sasang constitution: a pilot study" 한국한의학연구원 6 (6): 165-178, 2017

29 "DNA squencing costs: Data"

30 Kim S, "Comparison of commercial genetic-testing services in Korea with 23andMe service" 2014 : 539151-, 2014

31 이경주, "BRCA1/2 유전자 검사의 국내 시행 현황(2014)" 대한진단검사의학회 8 (8): 107-113, 2018

32 Kwon TB, "A study of HLA-DR polymorphism in four physical constitution groups classified by Korean traditional medicine" 58 : 91-101, 2000

33 Song NK, "A Study for the objective diagnosis by statistical analysis to the Bian Zheng questionnaire" 11 : 127-138, 2005